LPCN
Lipocine Inc.
Biotechnology · Healthcare · United States
1.52
close · 2026-10-29
value
84
cheaper than peers84
quality
28
stronger fundamentals28
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.58× | 93 |
| EV to EBITDA | 0.49× | 78 |
| price to sales | 10.98× | 52 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.2% | 92 |
| return on equity | -60.9% | 41 |
| operating margin | -1495.1% | 17 |
| revenue growth | -69.5% | 13 |
4 of 4 measures available
Facts
| market cap | $13M |
| free cash flow | -$6.9M |
| employees | 14 |
| first trade | 2013-10-22 |
| next earnings | not reported |
| fundamentals updated | 2026-08-20 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.77 | 0.00 | -3.14 | -2.21 | not reported |
| free cash flow | -$9.8M | -$1.3M | -$11.9M | -$12.1M | not reported |
| net income | -$9.6M | $8,352 | -$16.4M | -$10.8M | not reported |
| revenue | $2.0M | $11.2M | -$2.9M | $500,000 | not reported |
| unusual items | not reported | $17,166 | $212,690 | $815,940 | -$3.6M |